196 related articles for article (PubMed ID: 12231066)
1. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
George DJ
Urology; 2002 Sep; 60(3 Suppl 1):115-21; discussion 122. PubMed ID: 12231066
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
4. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
George D
Adv Exp Med Biol; 2003; 532():141-51. PubMed ID: 12908555
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
6. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
8. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
9. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Kurzrock R; Kantarjian HM; Druker BJ; Talpaz M
Ann Intern Med; 2003 May; 138(10):819-30. PubMed ID: 12755554
[TBL] [Abstract][Full Text] [Related]
10. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
11. A widening prospect: Imatinib and novel applications of targeted therapy.
Rowinsky EK
Semin Oncol; 2004 Apr; 31(2 Suppl 6):1-3. PubMed ID: 15175997
[No Abstract] [Full Text] [Related]
12. The biology of signal transduction inhibition: basic science to novel therapies.
Griffin J
Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
[TBL] [Abstract][Full Text] [Related]
13. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
Rosenberg A; Mathew P
Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
15. Treating imatinib-resistant leukemia: the next generation targeted therapies.
Burgess MR; Sawyers CL
ScientificWorldJournal; 2006 Aug; 6():918-30. PubMed ID: 16906325
[TBL] [Abstract][Full Text] [Related]
16. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
18. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
Wcislo G; Szarlej-Wcislo K; Szczylik C
J Cancer Res Clin Oncol; 2007 Aug; 133(8):533-8. PubMed ID: 17453242
[TBL] [Abstract][Full Text] [Related]
19. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
20. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]